Please login to the form below
What does the Five Year Forward View mean for pharma?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.
Introduction
to the 5YFV
When it was launched in October 2014, the Five Year Forward View (5YFV) was hailed as one of the most radical changes in the management and organisation of NHS England since its inception in 1948. Designed by NHS England and five partner organisations, it aims to put an end to the age-old divide between GPs with patients, and consultants with hospitals, and develop new, integrated and cost efficient models of care that suit local needs. In doing so, it aspires to create a sustainable NHS that continues to be funded by the taxpayer, is free at the point of use and able to meet the evolving needs of patients, now and in the future.
How can pharma capitalise on the 5YFV?
The 5YFV is dramatically changing the way that NHS services are run, particularly at a local level. One of the biggest changes here is the planned introduction of STPs – Sustainability and Transformation Plans – in 2017, which will help to deliver 5YFV by providing blueprints for delivering services locally. Instead of taking a one-size fits all approach to healthcare provision, STPs will see the commissioner/provider split replaced by local planning and management within 44 areas across England called ‘footprints’. These area-specific, whole-system plans will identify the health needs of their populations and define how they should be addressed quickly and effectively at a local level. Understanding the bigger picture in terms of how STPs will affect areas such as NHS structure, leadership, commissioning, KPIs, efficiency, procurement and patient pathways is crucial for pharma. The industry also needs to get to grips with the priorities and primary objectives of the individual 44 STPs. Armed with this knowledge, the industry should look to offer tailored solutions that fit in with the aspirations of individual STPs and will help them to fulfil the needs of their local patient populations.
Sharing best practice – how can pharma help?
Sharing best practice is key to accelerating the pace of change within the NHS and since October 2011, NHiS, which is part of Wilmington Healthcare, has been helping to do this through its Mental Health Commissioning Network conferences. The events, which are being sponsored this year by Lundbeck Ltd, Shire Ltd and Sunovion, bring like-minded people together to discuss and exchange ideas on how to treat people with mental health problems in a more integrated way. Wherever possible, they involve locally identified Chairs plus the Strategic Clinical Networks, Academic Health Science Networks and Public Health England. They provide an ideal opportunity for pharma companies to get involved in shaping patient pathways and improving NHS services in line with the objectives of 5YFV.
Conclusion
Since its inception in 2014, 5YFV has been dramatically changing the way that NHS services are run, particularly at local level, and further major changes will occur when STPs are introduced next year. In the midst of this upheaval, there are golden opportunities for pharma to get involved in redesigning NHS services. The key is to keep abreast of the changes, understand the bigger picture and find ways to utilise its expertise to add value.
Sue Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is director of NHS insight, both at Wilmington Healthcare. www.wilmingtonhealthcare.com
When it was launched in October 2014, the Five Year Forward View (5YFV) was hailed as one of the most radical changes in the management and organisation of NHS England since its inception in 1948. Designed by NHS England and five partner organisations, it aims to put an end to the age-old divide between GPs with patients, and consultants with hospitals, and develop new, integrated and cost efficient models of care that suit local needs. In doing so, it aspires to create a sustainable NHS that continues to be funded by the taxpayer, is free at the point of use and able to meet the evolving needs of patients, now and in the future.
How can pharma capitalise on the 5YFV?
The 5YFV is dramatically changing the way that NHS services are run, particularly at a local level. One of the biggest changes here is the planned introduction of STPs – Sustainability and Transformation Plans – in 2017, which will help to deliver 5YFV by providing blueprints for delivering services locally. Instead of taking a one-size fits all approach to healthcare provision, STPs will see the commissioner/provider split replaced by local planning and management within 44 areas across England called ‘footprints’. These area-specific, whole-system plans will identify the health needs of their populations and define how they should be addressed quickly and effectively at a local level. Understanding the bigger picture in terms of how STPs will affect areas such as NHS structure, leadership, commissioning, KPIs, efficiency, procurement and patient pathways is crucial for pharma. The industry also needs to get to grips with the priorities and primary objectives of the individual 44 STPs. Armed with this knowledge, the industry should look to offer tailored solutions that fit in with the aspirations of individual STPs and will help them to fulfil the needs of their local patient populations.
Sharing best practice – how can pharma help?
Sharing best practice is key to accelerating the pace of change within the NHS and since October 2011, NHiS, which is part of Wilmington Healthcare, has been helping to do this through its Mental Health Commissioning Network conferences. The events, which are being sponsored this year by Lundbeck Ltd, Shire Ltd and Sunovion, bring like-minded people together to discuss and exchange ideas on how to treat people with mental health problems in a more integrated way. Wherever possible, they involve locally identified Chairs plus the Strategic Clinical Networks, Academic Health Science Networks and Public Health England. They provide an ideal opportunity for pharma companies to get involved in shaping patient pathways and improving NHS services in line with the objectives of 5YFV.
Conclusion
Since its inception in 2014, 5YFV has been dramatically changing the way that NHS services are run, particularly at local level, and further major changes will occur when STPs are introduced next year. In the midst of this upheaval, there are golden opportunities for pharma to get involved in redesigning NHS services. The key is to keep abreast of the changes, understand the bigger picture and find ways to utilise its expertise to add value.
Sue Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is director of NHS insight, both at Wilmington Healthcare. www.wilmingtonhealthcare.com
Company Details
Wilmington Healthcare
01268 495600
Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom
Latest content on this profile
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- As well as creating new structures, the reforms underway within the NHS will see a considerable movement of people and power across the new Integrated Care Systems. Wilmington Healthcare’s Victoria Paxman looks at how the landscape of key influencers and decision-makers will change as a result.
Wilmington Healthcare
- We must be candid about our use of healthcare data if we want to win back public trust
- As the government announces a delay to a new GP data sharing initiative amid privacy concerns, Gareth Thomas, Managing Director of Wilmington Healthcare, explains why industry must move fast to rebuild public confidence.
Wilmington Healthcare
- Wilmington Healthcare appoints new Solutions Director
- Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare
Wilmington Healthcare
- Understanding the role of provider collaboratives
- Oli Hudson, Content Director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care.
Wilmington Healthcare
- How does the government plan to reshape the NHS?
- Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care
Wilmington Healthcare
- Integrated NHS finances: what do they mean for High Cost Drugs?
- Oli Hudson and Steve How, of Wilmington Healthcare, explore NHS England’s new system-level funding and its impact on prescribing for High Cost Drugs
Wilmington Healthcare
